

Long-term Follow-up of Patients With Spinal Muscular Atrophy Treated With OAV101 in Clinical Trials

NCT05335876

Status	RECRUITING
Phase	Phase 3
Sponsor	Novartis Pharmaceuticals
Enrollment	175 participants

Key Eligibility Criteria

Inclusion (3)

- Participated in an OAV101 clinical trial.
- Written informed consent must be obtained before any assessment is performed.
- Patient/Parent/legal guardian willing and able to comply with study procedures.

Locations (32 total)

Child Hosp Of The Kings Daughters, Norfolk, Virginia, United States
Novartis Investigative Site, Sydney, New South Wales, Australia
Novartis Investigative Site, Leuven, Belgium
... and 29 more locations